莫沙必利与多潘立酮治疗功能性消化不良的疗效观察  

Efficacy observation of mosapride and domperidone in the treatment of functional dyspepsia

作　　者：郝悦 HAO Yue(Dalian Central Hospital,Dalian 116033,China)

机构地区：[1]大连市中心医院,116033

出　　处：《中国实用医药》2021年第10期138-141,共4页China Practical Medicine

摘　　要：目的探讨莫沙必利与多潘立酮治疗功能性消化不良的临床疗效。方法 98例功能性消化不良患者,随机分为A组与B组,每组49例。A组应用莫沙必利治疗, B组应用多潘立酮治疗。对比两组患者的临床治疗效果、胃排空率、不良反应发生率及停药6个月后复发率。结果两组患者的治疗总有效率对比,差异无统计学意义(P>0.05)。治疗后, A组患者胃排空率(76.45±13.14)%明显高于B组的(56.13±12.49)%,差异具有统计学意义(P<0.05)。两组患者不良反应发生率对比,差异无统计学意义(P>0.05)。A组患者停药6个月后疾病复发率4.1%明显低于B组的16.3%,差异具有统计学意义(P<0.05)。结论莫沙必利治疗功能性消化不良有显著优势,其远期疗效优于多潘立酮,临床医生应根据实际情况选择用药。Objective To discuss the clinical efficacy of mosapride and domperidone in the treatment of functional dyspepsia. Methods A total of 98 patients with functional dyspepsia were randomly divided into group A and group B, with 49 cases in each group. Group A was treated with mosapride, and group B was treated with domperidone. The clinical effect, gastric emptying rate, incidence of adverse reactions and recurrence rate 6 months after drug withdrawal were compared between the two groups. Results There was no statistically significant difference in total effective rate between the two groups(P>0.05). After treatment, the gastric emptying rate(76.45±13.14)% of group A was obviously higher than(56.13±12.49)% of group B, and the difference was statistically significant(P<0.05). There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05). The recurrence rate 6 months after drug withdrawal 4.1% of group A was obviously lower than 16.3% of group B, and the difference was statistically significant(P<0.05). Conclusion Mosapride has significant advantages in the treatment of functional dyspepsia, and their long-term efficacy is better than domperidone. Clinicians should choose the drug according to the actual situation.

关 键 词：莫沙必利 多潘立酮 功能性消化不良 疗效观察 

分 类 号：R57[医药卫生—消化系统]